On 4 June 2019, the German Federal Court of Justice upheld a ruling by the German Federal Patent Court in which the latter court denied an application for a compulsory license under a patent related to the treatment of cholesterol-related disorders (Case X ZB 2/19). This decision is in line with previous German jurisprudence that has, with a few exceptions, been restrictive to grant compulsory licenses.
Continue Reading

On 6 September 2018, the German Federal Patent Court denied an application for a (preliminary) compulsory license under a patent related to the treatment of cholesterol-related disorders to the Applicant, group companies of a French pharmaceutical company (Case 3 LiQ 1/18). This decision is in line with previous jurisprudence of the court that has, with very few exceptions, been
Continue Reading

On 31 August 2016, the German Federal Patent Court issued a compulsory license under a patent that protects an HIV drug to affiliates of Merck & Co. (Case 3 LiQ 1/16). It was only the second time in the history of the court that a compulsory license has been granted and the first time that such license was granted in an emergency procedure. The Federal Patent Court’s first decision to grant a compulsory license dates back to 1991 (Case 3 Li 1/90) and did not survive appeal to the Federal Court of Justice (Case X ZR 26/92).
Continue Reading